Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis
Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025 PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.Peer-Reviewed Original ResearchAndrogen receptor pathway inhibitorsPSA responseProstate-specific antigen reductionAssociated with better OSProstate-specific antigenAndrogen deprivation therapyCastration-resistant PCOverall survivalProstate cancerTreated with androgen deprivation therapyHazard ratioMetastatic castration-resistant PCMetastatic hormone-sensitive PCNonmetastatic castration-resistant PCProstate-specific antigen responsePathway inhibitorBaseline PSA measurementHormone-sensitive PCUndetectable PSA levelsAdvanced prostate cancerAssociated with OSRandom-effects meta-analysesDeprivation therapyPSA levelsPSA measurements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply